Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camphoric Acid SCHEMBL12084182 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL2513165 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL30078310 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL23643 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL1738809 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL52395 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL12308 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL12083956 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL7099871 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 | |
| Camphoric Acid SCHEMBL27486599 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNAPOLBNPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-115746003-B | Methods of making and using PDE9 inhibitors | 卡都瑞恩医药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240246936-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC (US) | 2024-07-25 | — | — | US | disclosed |
| US-11926700-B2 | Methods and compositions for biorenewable polyesters derived from camphoric acid | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-116854630-A | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20230174711-A1 | METHODS AND COMPOSITIONS FOR BIORENEWABLE POLYESTERS DERIVED FROM CAMPHORIC ACID | NATIONAL SCIENCE FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| CN-115746003-A | Methods of making and using PDE9inhibitors | 伊马拉公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| CN-111183140-B | Methods of making and using PDE9 inhibitors | 伊马拉公司 | 2022-12-02 | — | — | CN | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2685981-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | Bristol-Myers Squibb Company (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| WO-2012125886-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-7704986-B2 | 5-(((3-((4-Hydroxy,1,5-dimethylhexyl)-2,2,3-(trimethyl)cyclopentyl)-2-propenylidene)cyclohexane-1,3-diol; induce bone matrix formation; mineralization without hypercalcemia; side effect reduction; bone disorders; osteomalacia, renal osteodystrophy, Paget's disease and osteoporosis; skin disorders | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20080032955-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-02-07 | — | — | US | disclosed |
| EP-0991619-B1 | INHIBITORS OF ALPHA 4-BETA 1 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246936-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, NUDT5, DHPS | ALDH1A1 1954/4885LMNA 4477/4885POLB 143/4885 |
| US-20230174711-A1 | METHODS AND COMPOSITIONS FOR BIORENEWABLE POLYESTERS DERIVED FROM CAMPHORIC ACID | HACL2, ADSL, AHCYL1 | ALDH1A1 643/4885LMNA 3203/4885POLB 2395/4885 |
| US-11926700-B2 | Methods and compositions for biorenewable polyesters derived from camphoric acid | HACL2, ADSL, DDT | ALDH1A1 452/4885LMNA 3177/4885POLB 1822/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | ALDH1A1 3567/4885LMNA 4305/4885POLB 3209/4885 |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | ALDH1A1 2145/4885LMNA 4832/4885POLB 1988/4885 |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | ALDH1A1 100/4885LMNA 2264/4885POLB 3069/4885 |
| US-20080032955-A1 | VITAMIN D3 ANALOGUES FOR THE PREVENTION AND TREATMENT OF BONE DISORDERS | VDR, CYP24A1, CYP2R1 | ALDH1A1 4226/4885LMNA 531/4885POLB 2845/4885 |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885LMNA 4564/4885POLB 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.